In today’s world of evolving healthcare, pricing pressures, and barriers to market access, pharmaceutical manufacturers need strong evidence to prove that their products deliver superior clinical outcomes and demonstrate economic value in order to meet stringent payer requirements. Currently, several global reimbursement agencies formally ask for HEOR information for their standard assessment process, including the National Institute for Health and Clinical Excellence in the United Kingdom, Spanish health technology assessment (HTA) agencies, the Korean Health Insurance Review Agency, and the Health Intervention and Technology Assessment Program in Thailand.1-3 Therefore, in order to gain market access and remain competitive, manufacturers must generate evidence to demonstrate clinical and economic benefit to providers, payers, and healthcare decision makers.
Generating the evidence takes profound analytical expertise; a deep understanding of payers, providers, and patients; and actionable insights that will position products for ongoing success. HEOR analysis gives a precise picture of a product’s clinical position in the market, usage patterns, uptake trends, and more. As a consequence, pharmaceutical manufacturers invest heavily in HEOR studies alongside clinical trials in order to collect clinical, economic, and humanistic real-world data throughout the lifecycle of a product.1 Usually, a value proposition for a product is developed on the basis of findings from phase II research, anticipated significant endpoints from phase III research, and factors considered by clinicians to be the principal treatment and outcome issues. Over the past few decades, HEOR has advanced considerably in methodology and scientific rigor. The various types of HEOR studies include systematic literature reviews (with/without meta-analyses), retrospective database analyses (using payer claims, electronic medical records, or survey data), clinical trial data analyses, economic analyses (burden of illness, cost-effectiveness, and cost-utility), decision-analytic modeling, budget-impact analyses, and global value dossiers.